Vaso Corporation reported a total revenue of $89.1 million for the fiscal year ending December 31, 2025, marking a 2.7% increase from $86.8 million in 2024. The company achieved a net income of $1.57 million, a significant rise of 65% compared to the previous year's net income of $951,000. This increase in profitability was primarily attributed to a higher income tax benefit and a gain from the sale of its VHC-IT business unit. Earnings per share remained stable at $0.01 for both years.
In terms of segment performance, the IT segment experienced a slight decline in revenue, generating $42.5 million in 2025, down from $42.9 million in 2024. This decrease was largely due to the divestiture of the healthcare IT services unit. Conversely, the professional sales service segment saw a revenue increase of 6.9%, totaling $44.2 million, driven by a higher volume of GE HealthCare equipment sales and an improved commission rate. The equipment segment reported a minor revenue decrease to $2.44 million, influenced by lower deliveries in China, although U.S. operations saw a notable increase in software-as-a-service revenues.
Operationally, Vaso Corporation's employee count stood at 282 as of December 31, 2025, with a significant portion dedicated to the professional sales service segment, which employs over 90 sales professionals. The company has also recorded a deferred commission revenue of $38.6 million, reflecting a 10.3% increase from the previous year, indicating a backlog of orders that exceeds equipment deliveries. This backlog is a positive indicator of future revenue potential as orders are fulfilled.
Strategically, Vaso Corporation has undergone significant changes, including the sale of its VHC-IT business to Nano-X Imaging Ltd. in November 2025. The company continues to focus on expanding its product offerings and enhancing market penetration, particularly in the professional sales service segment. The management has outlined plans to control operating costs amid inflationary pressures and to explore new revenue models within its equipment segment. The company also aims to maintain compliance with regulatory requirements and to optimize its business portfolio for future growth.
Looking ahead, Vaso Corporation anticipates generating sufficient cash flow from operations to meet its obligations over the next twelve months. The company had cash and cash equivalents of $35.1 million at year-end and expects to leverage its existing resources to support ongoing operations and strategic initiatives. The management remains optimistic about the potential for growth, particularly in light of the extended agreement with GE HealthCare, which is now set to run through December 31, 2030.
About VASO Corp
Vaso Corporation operates in healthcare equipment and information technology, focusing on three segments: healthcare IT services, medical device manufacturing, and healthcare capital equipment sales. It provides managed network solutions, proprietary cardiovascular devices, and sales of GE Healthcare diagnostic equipment. Serving domestic and international markets, the company leverages proprietary technology, strategic partnerships, and a diversified product portfolio to deliver healthcare solutions and services.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.